The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Building better monoclonal antibody-based therapeutics
Open accessAbstract
For 20 years, monoclonal antibodies (mAbs) have been a standard component of cancer therapy, but there is still much room for improvement. Efforts continue to build better cancer therapeutics based on mAbs. Anticancer mAbs function through various mechanisms, including directly targeting the malignant cells, modifying the host response, delivering cytotoxic moieties and retargeting cellular immunity towards the malignant cells. Characteristics of mAbs that affect their efficacy include antigen specificity, overall structure, affinity for the target antigen and how a mAb component is incorporated into a construct that can trigger target cell death. This Review discusses the various approaches to using mAb-based therapeutics to treat cancer and the strategies used to take advantage of the unique potential of each approach, and provides examples of current mAb-based treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Wen, P. Y., Macdonald, D. R., Reardon, D. A., Cloughesy, T. F., Sorensen, A. G., Galanis, E., DeGroot, J., Wick, W., Gilbert, M. R., Lassman, A. B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.3541 · Cited by 3,836
Trastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A., Scott, E. C., Gutierrez, M., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,560
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma
Yu, A. L., Gilman, A. L., Ozkaynak, M. F., London, W. B., Kreissman, S. G., Chen, H. X., Smith, M., Anderson, B., Villablanca, J. G., Matthay, K. K., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0911123 · Cited by 1,835
Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774
Maloney, D. G., Grillo-López, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., et al. (1997) · Blood · doi:10.1182/blood.v90.6.2188 · Cited by 1,733
Younes, A., Gopal, A. K., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J., Ramchandren, R., Bartlett, N. L., Cheson, B. D., de Vos, S., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0410 · Cited by 1,529
Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.11.076 · Cited by 1,170
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., & Sliwkowski, M. X. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00083-2 · Cited by 1,120
Shen, B.-Q., Xu, K., Liu, L., Raab, H., Bhakta, S., Kenrick, M., Parsons-Reponte, K. L., Tien, J., Yu, S.-F., Mai, E., et al. (2012) · Nature Biotechnology · doi:10.1038/nbt.2108 · Cited by 1,008
Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006
The ERBB network: at last, cancer therapy meets systems biology
Yarden, Y., & Pines, G. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3309 · Cited by 988
Mössner, E., Brünker, P., Moser, S., Püntener, U., Schmidt, C., Herter, S., Grau, R., Gerdes, C., Nopora, A., van Puijenbroek, E., et al. (2010) · Blood · doi:10.1182/blood-2009-06-225979 · Cited by 981
Topp, M. S., Kufer, P., Gökbuget, N., Goebeler, M., Klinger, M., Neumann, S., Horst, H.-A., Raff, T., Viardot, A., Schmid, M., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.7270 · Cited by 913
Rituximab: Mechanism of Action
Weiner, G. J. (2010) · Seminars in Hematology · doi:10.1053/j.seminhematol.2010.01.011 · Cited by 786
Self-citationAntibody-Drug Conjugates in Cancer Therapy
Sievers, E. L., & Senter, P. D. (2013) · Annual Review of Medicine · doi:10.1146/annurev-med-050311-201823 · Cited by 770
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Maude, S. L., Barrett, D., Teachey, D. T., & Grupp, S. A. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000035 · Cited by 752
The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD20
Teeling, J. L., Mackus, W. J. M., Wiegman, L. J. J. M., van den Brakel, J. H. N., Beers, S. A., French, R. R., van Meerten, T., Ebeling, S., Vink, T., Slootstra, J. W., et al. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.1.362 · Cited by 609
Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies
Shan, D., Ledbetter, J. A., & Press, O. W. (1998) · Blood · doi:10.1182/blood.v91.5.1644 · Cited by 576
Radioimmunotherapy of B-Cell Lymphoma with [131I]Anti-B1 (Anti-CD20) Antibody
Kaminski, M. S., Zasadny, K. R., Francis, I. R., Milik, A. W., Ross, C. W., Moon, S. D., Crawford, S. M., Burgess, J. M., Petry, N. A., Butchko, G. M., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199308123290703 · Cited by 547
Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.
LoBuglio, A. F., Wheeler, R. H., Trang, J., Haynes, A., Rogers, K., Harvey, E. B., Sun, L., Ghrayeb, J., & Khazaeli, M. B. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.11.4220 · Cited by 524
Mechanisms of killing by anti-CD20 monoclonal antibodies
Glennie, M. J., French, R. R., Cragg, M. S., & Taylor, R. P. (2007) · Molecular Immunology · doi:10.1016/j.molimm.2007.06.151 · Cited by 515
Immune Modulation in Cancer with Antibodies
Page, D. B., Postow, M. A., Callahan, M. K., Allison, J. P., & Wolchok, J. D. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-092012-112807 · Cited by 515
Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
Peggs, K. S., Quezada, S. A., Korman, A. J., & Allison, J. P. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.01.011 · Cited by 445
Rituximab-Dependent Cytotoxicity by Natural Killer Cells
Dall’Ozzo, S., Tartas, S., Paintaud, G., Cartron, G., Colombat, P., Bardos, P., Watier, H., & Thibault, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2862 · Cited by 434
Tumor inhibitors. LXXIII. Maytansine, a novel antileukemic ansa macrolide from Maytenus ovatus
Kupchan, S. M., Komoda, Y., Court, W. A., Thomas, G. J., Smith, R. M., Karim, A., Gilmore, C. J., Haltiwanger, R. C., & Bryan, R. F. (1972) · Journal of the American Chemical Society · doi:10.1021/ja00759a054 · Cited by 434
A clinical trial of anti-idiotype therapy for B cell malignancy
Meeker, T., Lowder, J., Maloney, D., Miller, R., Thielemans, K., Warnke, R., & Levy, R. (1985) · Blood · doi:10.1182/blood.v65.6.1349.bloodjournal6561349 · Cited by 416
Nadler, L. M., Stashenko, P., Hardy, R., Kaplan, W. D., Button, L. N., Kufe, D. W., Antman, K. H., & Schlossman, S. F. (1980) · PubMed · Cited by 413
Passive immunity in prevention and treatment of infectious diseases
Keller, M. A., & Stiehm, E. R. (2000) · Clinical Microbiology Reviews · doi:10.1128/cmr.13.4.602 · Cited by 388
Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
Shan, D., Ledbetter, J. A., & Press, O. W. (2000) · Cancer Immunology, Immunotherapy · doi:10.1007/s002620050016 · Cited by 385
Chimeric Antigen Receptor Therapy for Cancer
Barrett, D. M., Singh, N., Porter, D. L., Grupp, S. A., & June, C. H. (2014) · Annual Review of Medicine · doi:10.1146/annurev-med-060512-150254 · Cited by 349
Fc receptors are required in passive and active immunity to melanoma
Clynes, R., Takechi, Y., Moroi, Y., Houghton, A., & Ravetch, J. V. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.2.652 · Cited by 321
Maturing antibody–drug conjugate pipeline hits 30
Mullard, A. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4009 · Cited by 295
Alduaij, W., Ivanov, A., Honeychurch, J., Cheadle, E. J., Potluri, S., Lim, S. H., Shimada, K., Chan, C. H. T., Tutt, A., Beers, S. A., et al. (2011) · Blood · doi:10.1182/blood-2010-07-296913 · Cited by 294
Targeting HER2 for the Treatment of Breast Cancer
Rimawi, M. F., Schiff, R., & Osborne, C. K. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-042513-015127 · Cited by 268
Controlling escape from angiogenesis inhibitors
Sennino, B., & McDonald, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3366 · Cited by 264
Pawluczkowycz, A. W., Beurskens, F. J., Beum, P. V., Lindorfer, M. A., van de Winkel, J. G. J., Parren, P. W. H. I., & Taylor, R. P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0900632 · Cited by 262
Clinical radioimmunotherapy—the role of radiobiology
Pouget, J.-P., Navarro-Teulon, I., Bardiès, M., Chouin, N., Cartron, G., Pèlegrin, A., & Azria, D. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.160 · Cited by 250
Shusterman, S., London, W. B., Gillies, S. D., Hank, J. A., Voss, S. D., Seeger, R. C., Reynolds, C. P., Kimball, J., Albertini, M. R., Wagner, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.8861 · Cited by 248
Hinman, L. M., Hamann, P. R., Wallace, R., Menendez, A. T., Durr, F. E., & Upeslacis, J. (1993) · PubMed · Cited by 236
Bowles, J. A., Wang, S.-Y., Link, B. K., Allan, B., Beuerlein, G., Campbell, M.-A., Marquis, D., Ondek, B., Wooldridge, J. E., Smith, B. J., et al. (2006) · Blood · doi:10.1182/blood-2006-04-020057 · Cited by 227
Self-citationZolot, R. S., Basu, S., & Million, R. P. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd3980 · Cited by 227
Gopal, A. K., Chen, R., Smith, S. E., Ansell, S. M., Rosenblatt, J. D., Savage, K. J. J., Connors, J. M., Engert, A., Larsen, E. K. M., Chi, X., et al. (2014) · Blood · doi:10.1182/blood-2014-08-595801 · Cited by 225
Pedersen, I. M., Buhl, A. M., Klausen, P., Geisler, C. H., & Jurlander, J. (2002) · Blood · doi:10.1182/blood.v99.4.1314 · Cited by 219
Astatine-211: Production and Availability
R. Zalutsky, M., & Pruszynski, M. (2011) · Current Radiopharmaceuticalse · doi:10.2174/1874471011104030177 · Cited by 200
Wang, S.-Y., Racila, E., Taylor, R. P., & Weiner, G. J. (2008) · Blood · doi:10.1182/blood-2007-02-074716 · Cited by 194
Self-citationHernandez‐Ilizaliturri, F. J., Jupudy, V., Ostberg, J. R., Oflazoglu, E., Huberman, A., Repasky, E. A., & Czuczman, M. S. (2003) · PubMed · Cited by 188
Salles, G., Morschhauser, F., Lamy, T., Milpied, N., Thieblemont, C., Tilly, H., Bieska, G., Asikanius, E., Carlile, D., Birkett, J., et al. (2012) · Blood · doi:10.1182/blood-2012-01-404368 · Cited by 187
Beers, S. A., Chan, C. H. T., James, S., French, R. R., Attfield, K. E., Brennan, C. M., Ahuja, A., Shlomchik, M. J., Cragg, M. S., & Glennie, M. J. (2008) · Blood · doi:10.1182/blood-2008-04-149161 · Cited by 180
Angiogenesis modulation in cancer research: novel clinical approaches
Cristofanilli, M., Charnsangavej, C., & Hortobagyi, G. N. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd819 · Cited by 179
Collected Studies on Immunity.
(1906) · Journal of the American Medical Association · doi:10.1001/jama.1906.02520030066027 · Cited by 177
Actinium-225 in targeted alpha-particle therapeutic applications.
A. Scheinberg, D., & R. McDevitt, M. (2011) · Current Radiopharmaceuticalse · doi:10.2174/1874471011104040306 · Cited by 176
Navid, F., Sondel, P. M., Barfield, R., Shulkin, B. L., Kaufman, R. A., Allay, J. A., Gan, J., Hutson, P., Seo, S., Kim, K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.4423 · Cited by 165
Bispecific antibodies in cancer therapy
Segal, D. M., Weiner, G. J., & Weiner, L. M. (1999) · Current Opinion in Immunology · doi:10.1016/s0952-7915(99)00015-1 · Cited by 161
Self-citationSondak, V. K., Smalley, K. S. M., Kudchadkar, R. R., Grippon, S., & Kirkpatrick, P. N. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3463 · Cited by 158
Cartron, G., de Guibert, S., Dilhuydy, M., Morschhauser, F., Leblond, V., Dupuis, J., Mahé, B., Bouabdallah, R., Lei, G., Wenger, M., et al. (2014) · Blood · doi:10.1182/blood-2014-07-586610 · Cited by 157
Trastuzumab in the Treatment of Metastatic Breast Cancer
Feldman, A. M., Lorell, B. H., & Reís, S. E. (2000) · Circulation · doi:10.1161/01.cir.102.3.272 · Cited by 152
Ehrlich, P., Bolduan, C. F., & Howard (1907) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-190708000-00032 · Cited by 152
CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells
Bowles, J. A., & Weiner, G. J. (2005) · Journal of Immunological Methods · doi:10.1016/j.jim.2005.06.018 · Cited by 148
Self-citationWang, S., Veeramani, S., Racila, E. V., Cagley, J. R., Fritzinger, D. C., Vogel, C.-W., John, W. S., & Weiner, G. J. (2009) · Blood · doi:10.1182/blood-2009-01-200469 · Cited by 143
Self-citationBeum, P. V., Peek, E. M., Lindorfer, M. A., Beurskens, F. J. M., Engelberts, P. J., Parren, P. W. H. I., van de Winkel, J. G. J., & Taylor, R. P. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101189 · Cited by 140
Complement in monoclonal antibody therapy of cancer
Rogers, L. M., Veeramani, S., & Weiner, G. J. (2014) · Immunologic Research · doi:10.1007/s12026-014-8542-z · Cited by 138
Self-citationDalle, S., Reslan, L., de Horts, T. B., Herveau, S., Herting, F., Pleșa, A., Friess, T., Umaña, P., Klein, C., & Dumontet, C. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0385 · Cited by 131
Tannir, N. M., Forero, A., Ramchandren, R., Pal, S. K., Ansell, S. M., Infante, J. R., de Vos, S., Hamlin, P. A., Kim, S. K., Whiting, N. C., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0151-0 · Cited by 128
SNAKE VENOM IN RELATION TO HÆMOLYSIS, BACTERIOLYSIS, AND TOXICITY
Flexner, S., & Noguchi, H. (1902) · The Journal of Experimental Medicine · doi:10.1084/jem.6.3.277 · Cited by 122
Сергеева, А., Alatrash, G., He, H., Ruisaard, K. E., Lu, S., Wygant, J. N., McIntyre, B. W., Ma, Q., Li, D., John, L. S. S., et al. (2011) · Blood · doi:10.1182/blood-2010-07-299248 · Cited by 120
Lefebvre, M.-L., Krause, S. W., Salcedo, M., & Nardin, A. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000203081.43235.d7 · Cited by 111
Chen, S., Yu, L., Jiang, C., Zhao, Y., Da Yu, S. U. N., Li, S., Liao, G., Chen, Y., Fu, Q., Tao, Q., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.108 · Cited by 110
Complement and cellular cytotoxicity in antibody therapy of cancer
Wang, S., & Weiner, G. J. (2008) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.8.6.759 · Cited by 110
Self-citationBendell, J. C., Saleh, M. N., Rose, A. A. N., Siegel, P. M., Hart, L. L., Sirpal, S., Jones, S. F., Green, J., Crowley, E. M., Simantov, R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.52.5683 · Cited by 108
Antibody-enhanced cross-presentation of self antigen breaks T cell tolerance
Harbers, S. O., Crocker, A., Catalano, G., D’Agati, V. D., Jung, S., Desai, D. D., & Clynes, R. (2007) · Journal of Clinical Investigation · doi:10.1172/jci29470 · Cited by 107
Ribrag, V., Dupuis, J., Tilly, H., Morschhauser, F., Lainé, F., Houot, R., Haïoun, C., Copie‐Bergman, C., Varga, A., Lambert, J. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0580 · Cited by 105
Optimization of Radioimmunotherapy of Solid Tumors: Biological Impediments and Their Modulation
Jain, M., Venkatraman, G., & Batra, S. K. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2436 · Cited by 104
Immunotherapy of lymphoma and leukemia with T-cell engaging BiTE antibody blinatumomab
Nagorsen, D., Bargou, R. C., Rüttinger, D., Kufer, P., Baeuerle, P. A., & Zugmaier, G. (2009) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190902943077 · Cited by 102
Ott, P. A., Hamid, O., Pavlick, A. C., Kluger, H. M., Kim, K. B., Boasberg, P. D., Simantov, R., Crowley, E. M., Green, J. A., Hawthorne, T. R., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8115 · Cited by 97
Tutt, A. L., French, R. R., Illidge, T., Honeychurch, J., McBride, H. M., Penfold, C. A., Fearon, D. T., Parkhouse, R. M. E., Klaus, G. G. B., & Glennie, M. J. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.6.3176 · Cited by 95
Lima, A. B. C., Macedo, L. T., & Sasse, A. D. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022681 · Cited by 92
Lavaud, P., & André, F. (2014) · BMC Medicine · doi:10.1186/s12916-014-0132-3 · Cited by 87
Bernard, A., & Boumsell, L. (1984) · Human Immunology · doi:10.1016/0198-8859(84)90051-x · Cited by 84
Vaughan, A. T., Iriyama, C., Beers, S. A., et al. (2013) · Blood · doi:10.1182/blood-2013-04-490821 · Cited by 79
The high‐affinity FcγRI on PMN: regulation of expression and signal transduction
Hoffmeyer, F., Witte, K. K., & Schmidt, R. E. (1997) · Immunology · doi:10.1046/j.1365-2567.1997.00381.x · Cited by 76
Lohse, S., Derer, S., Beyer, T. D., Klausz, K., Peipp, M., Leusen, J. H. W., van de Winkel, J. G. J., Dechant, M., & Valerius, T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1003082 · Cited by 67
CAR-T cell therapy seeks strategies to harness cytokine storm
DeFrancesco, L. (2014) · Nature Biotechnology · doi:10.1038/nbt0714-604 · Cited by 64
T-cell therapy at the threshold
June, C. H., Rosenberg, S. A., Sadelain, M., & Weber, J. S. (2012) · Nature Biotechnology · doi:10.1038/nbt.2305 · Cited by 59
Immunotoxins in the therapy of cancer: From bench to clinic
Ghetie, V. F., & Vitetta, E. S. (1994) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(94)90025-6 · Cited by 58
Dubrovsky, L., Pankov, D., Brea, E. J., et al. (2014) · Blood · doi:10.1182/blood-2014-01-549022 · Cited by 52
Natsume, A., Shimizu‐Yokoyama, Y., Satoh, M., Shitara, K., & Niwa, R. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01327.x · Cited by 40
Witzig, T. E., Wiseman, G. A., Maurer, M. J., Habermann, T. M., Micallef, I. N., Nowakowski, G. S., Ansell, S. M., Colgan, J. P., Inwards, D. J., Porrata, L. F., et al. (2013) · American Journal of Hematology · doi:10.1002/ajh.23460 · Cited by 36
Self-citationde Goeij, B. E. C. G., Peipp, M., de Haij, S., van den Brink, E. N., Kellner, C., Riedl, T., de Jong, R. N., Vink, T., Strumane, K., Bleeker, W. K., et al. (2014) · mAbs · doi:10.4161/mabs.27705 · Cited by 35
Differential signaling by an anti-p185(HER2) antibody and heregulin.
Xiao, L., Vadlamudi, R. K., McWatters, A., Bae, D. S., Mills, G. B., Kumar, R., & Bast, R. C. (2000) · PubMed · Cited by 28
Picking the Optimal Target for Antibody-Drug Conjugates
Mathur, R., & Weiner, G. J. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.e103 · Cited by 27
Self-citationFrom the structure of antibodies to the diversification of the immune response
Milstein, C. (1985) · Bioscience Reports · doi:10.1007/bf01116899 · Cited by 7
From the Structure of Antibodies to the Diversification of the Immune Response
Milstein, C. (2004) · Bioscience Reports · doi:10.1007/s10540-005-2735-6 · Cited by 6
Cited by
Development of therapeutic antibodies for the treatment of diseases
Lu, R.-M., Hwang, Y.-C., Liu, I.-J., Lee, C.-C., Tsai, H.-Z., Li, H.-J., & Wu, H.-C. (2020) · Journal of Biomedical Science · doi:10.1186/s12929-019-0592-z · Cited by 2,085
A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Sanmamed, M. F., & Chen, L. (2018) · Cell · doi:10.1016/j.cell.2018.09.035 · Cited by 1,392
Chehelgerdi, M., Chehelgerdi, M., Allela, O. Q. B., Pecho, R. D. C., Jayasankar, N., Rao, D. P., Thamaraikani, T., Vasanthan, M., Viktor, P., Lakshmaiya, N., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01865-0 · Cited by 1,062
Beyond binding: antibody effector functions in infectious diseases
Lu, L. L., Suscovich, T. J., Fortune, S. M., & Alter, G. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.106 · Cited by 825
Antibody–drug conjugates for cancer
Chau, C. H., Steeg, P. S., & Figg, W. D. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31774-x · Cited by 816
Metadata
- Authors
- Weiner, G. J.
- Venue
- Nature Reviews Cancer
- Published
- 2015-05-22
- Volume
- 15
- Issue
- 6
- Pages
- 361-370
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1758612015
- Cited by
- 712
- References
- 111
- FWCI
- 13.81
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.